Log in | Register

Roche Basel's MAB95 Facility Named 2009 Facility of the Year Award Overall Winner

For the latest pharmaceutical news and updates - Sign up now!
Loading...
ISPE, a global not-for-profit association of 24,000 technical professionals working in the manufacturing and drug development sectors of the pharmaceutical industry, announced during the Keynote Session at its 2009 Annual Meeting in San Diego, California, USA, that Roche Pharma Biotech Production Basel's Monoclonal Anti Bodies (MAB) 95 Facility is the overall winner of the 2009 Facility of the Year Awards (FOYA) program.

Located in Basel, Switzerland, Roche's unique vertical MAB Facility was named the overall 2009 Facility of the Year Award winner in part because of the innovative way in which it was planned, designed, and constructed on the site of a former chemical production plant in a busy residential area. Through teamwork, innovative design, and precise construction management, the state-of-the-art project was successfully realized in only 35 months, six weeks ahead of an already aggressive schedule and nine percent under budget.

Standing 40 meters tall with eight floors above ground and two floors underground, the small building footprint and absence of adjacent construction lay-down areas tested the ingenuity of the project team at every turn. To reduce congestion in and around the already tight project site, cutting-edge communication technology was applied whenever possible in the day-to-day running of the project. As the facility had to be arranged vertically, and as all systems were fully integrated, the normal option of sequential completion proved to be too slow when modeled in the schedule, forcing the project team to develop tactics to complete the whole facility as a single entity (i.e., work on everything in parallel). The 2009 FOYA Judging Panel felt that Roche's project team competently faced these and many other project challenges to produce a truly cutting-edge manufacturing facility.

Roche's MAB 95 Facility was selected as the Overall 2009 Facility of the Year Award winner by a judging panel consisting of eight prominent pharmaceutical industry professionals. It was one of six Category Winners that included:
· Aseptic Technologies, located in Gembloux, Belgium, winner of the Facility of the Year Award for Equipment Innovation
· Centocor Biologics Ireland, located in Ringaskiddy, Cork, Ireland, winner of the Facility of the Year Award for Sustainability
· Centocor R&D Schaffhausen, located in Schaffhausen, Switzerland, winner of the Facility of the Year Award for Facility Integration
· hameln pharma, located in Hameln, Germany, winner of the Facility of the Year Award for Operational Excellence
· Orchid Chemicals & Pharmaceuticals, located in Aurangabad, India, winner of the Facility of the Year Award for Regional Excellence
In addition, GlaxoSmithKline Manufacturing was awarded an Honorable Mention for the company's project in Verona, Italy.

Sponsored by ISPE, INTERPHEX, and Pharmaceutical Processing magazine, the Facility of the Year Awards (FOYA) recognizes state-of-the-art pharmaceutical manufacturing projects that utilize new and innovative technologies to enhance the delivery of a quality project, as well as reduce the cost of producing high-quality medicines. Now in its sixth year, the awards program effectively spotlights the accomplishments, shared commitment, and dedication of individuals in companies worldwide to innovate and advance pharmaceutical manufacturing technology for the benefit of all global consumers.
Join the Discussion
Rate Article:  Average 0 out of 5
register or log in to comment on this article!

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

Blogs

The Tale of Two Deviations

The Tale of Two Deviations

Apr 23 | The QA Pharm

It stands to reason that pharmaceutical companies in compliance trouble also have problems with their Deviation Management and Corrective and Preventive Action (CAPA) System(s).

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Can the Combination of Creative Destruction and “Steve Jobs’ Traits” Lead to a “Pharma QbD Spring”?

Apr 16 | Girish Malhotra, PE, President, EPCOT International

The answer is an unequivocal yes but we need some outsiders who can conspire with the insiders who will be the flag bearers within the companies. Outsiders can be the counsels/co-conspirators to the insiders for the coup d'etat.

Multimedia

Merck - 2012 Facility of the Year Award - Facility Integration

Merck - 2012 Facility of the Year Award - Facility Integration

May 14 | Video

Brian Morrissey, Senior Project Engineer, Merck Manufacturing Division, talks to Pharmaceutical Processing's Editor In Chief Mike Auerbach during INTERPHEX 2012 about the company's Vaccine Bulk Manufacturing Facility Program of Projects. The facility has won the Facility Integration award in the 2012 Facility of the Year Award competition sponsored by ISPE, INTERPHEX and Pharmaceutical Processing magazine.

Medicine from a Vending Machine?

Medicine from a Vending Machine?

May 3 | Video

A Chinese company is pushing for acceptance of traditional Chinese medicine with a machine that can dispense herbs.

Taking Precautions to Prevent Contagion

Taking Precautions to Prevent Contagion

Apr 29 | Video

With the recent outbreak of viruses such as SARS, bird flu and swine flu, officials and travelers are being extra careful about preventing the illnesses from being transmitted.

Measles Infections on the Rise in the U.S.

Measles Infections on the Rise in the U.S.

Apr 20 | Video

Just over a decade ago, U.S. health officials believed measles would be eradicated, but according to a new report from the Centers for Disease Control, infections are back and the numbers are growing. Dr. Nancy Snyderman, NBC's Chief Medical Editor reports.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter